The 1F2 mAb reacts with Crry/p65, a cell-surface protein that blocks complement activation and C3 deposition by both the classical and alternative pathways. Based on nucleotide sequence identity, Crry/p65 is the genetic homologue of human CR1 (Complement Receptor 1). However, it has been proposed that Crry/p65 is the functional homologue of human MCP (Membrane Cofactor Protein) and/or DAF (Decay-Accelerating Factor), due to the similar functions these proteins share and the fact that Crry/p65 does not display CR1's complement-receptor activity. Crry/p65 is expressed in most organs, such as thymus, kidney, uterus, skin, lung, pancreas, heart, stomach, large and small intestine, and spleen. Platelets, brain, and muscle express low, but detectable levels of Crry/p65. In addition, Crry/p65 is expressed in J774 cells, bone marrow-derived macrophages, and thioglycollate-elicited peritoneal macrophages, as determined by RT-PCR. Crry is crucial in the regulation of complement activation during early mouse embryonic development and essential in fetomaternal tolerance. The 1F2 mAb partially blocks Crry/p65-mediated complement protection in vitro.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD CompBead to ensure that BD CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Researchers should determine the optimal concentration of this reagent for their individual applications.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Alexa Fluor® is a registered trademark of Life Technologies Corporation.
6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
8. This product is provided under an Agreement between BIOTIUM and BD Biosciences. This product, and only in the amount purchased by buyer, may be used solely for buyer’s own internal research, in a manner consistent with the accompanying product literature. No other right to use, sell or otherwise transfer (a) this product, or (b) its components is hereby granted expressly, by implication or by estoppel. This product is for research use only. Diagnostic uses require a separate license from Biotium, Inc. For information on purchasing a license to this product including for purposes other than research, contact Biotium, Inc., 3159 Corporate Place, Hayward, CA 94545, Tel: (510) 265-1027. Fax: (510) 265-1352. Email:
[email protected].
